Clinical Trial Update: Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD

View source ↗

Summary

The study evaluating non-small cell lung cancer patients in the US initiating an approved therapy with risk of pneumonitis/ILD has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Status: TERMINATED